Sign in to view content

BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)

Michael A. Singer, MD

Video
Published 2024

Related

Retinitis Pigmentosa With Cystoid Macular Edema
Zachary M Bodnar, MD
Retina Image Bank: Images of the Week
2018
Phase 1/2 Clinical Trial of Intravitreal 4D-125 AAV Gene Therapy in Patients with Advanced XLRP: Interim Safety & Preliminary Activity
Cagri G Besirli, MD, PhD, FASRS
Updates from the Field
2021
Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase 2 Skyline Trial
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2024

Category: Hereditary Retinal Disease & Genetics

See more